Pyxis Oncology, Inc.: management transactions · United States · SEC (Form 4)

About Pyxis Oncology, Inc.

Pyxis Oncology, Inc. (ticker: PYXS) is a U.S.-listed biotechnology company traded on the NASDAQ in the United States, and it belongs squarely in the healthcare and pharma complex. The company was founded in June 2018 and launched operations in July 2019. Its headquarters are in Boston, Massachusetts, a leading U.S. biotech cluster. From inception, Pyxis has been built around an oncology thesis focused on the tumor microenvironment, aiming to create therapies that can directly attack cancer cells while also addressing immune suppression and immune evasion. ([ir.pyxisoncology.com](https://ir.pyxisoncology.com/static-files/be1b7460-c18f-41f5-b85d-de9ec789acdd?utm_source=openai)) Pyxis Oncology’s business model is centered on a clinical-stage pipeline with an emphasis on antibody-drug conjugates (ADCs) and selected immuno-oncology programs. The company’s core approach is to deliver highly potent payloads directly to tumor tissue through targeted biologics, which may offer a more selective therapeutic profile than conventional chemotherapy. Its lead and most closely watched asset is PYX-201, a clinical-stage ADC, supported by additional programs and platform capabilities. The pipeline was broadened materially through the acquisition of Apexigen in 2023, which added antibody-generation rights and strengthened the company’s development toolkit. ([ir.pyxisoncology.com](https://ir.pyxisoncology.com/news-releases/news-release-details/pyxis-oncology-advances-pyx-106-and-pyx-201-clinical-programs?utm_source=openai)) In competitive terms, Pyxis occupies a crowded but strategically important niche: clinical-stage oncology biotech. It competes with larger pharmaceutical companies and specialist ADC/immuno-oncology players, so its differentiation depends on scientific novelty, clinical execution, and smart partnering. The company has highlighted collaboration with Merck for a clinical study combining PYX-201 with KEYTRUDA, which is a meaningful validation point for the program’s strategic relevance. Pyxis is targeting difficult solid tumors, including head and neck cancer, breast cancer, and certain sarcoma settings, where unmet medical need remains high and successful clinical data could be commercially significant. ([ir.pyxisoncology.com](https://ir.pyxisoncology.com/news-releases/news-release-details/pyxis-oncology-announces-favorable-preliminary-pyx-201-clinical/?utm_source=openai)) Recent developments have remained centered on clinical progress and capital discipline. In March 2026, Pyxis reported its full-year 2025 results and stated that cash and cash equivalents were expected to fund operations into the fourth quarter of 2026. The company also indicated that additional preclinical and clinical data disclosures are expected in 2026, while management changes have supported the next phase of execution. For investors, PYXS is best viewed as a high-risk, high-upside oncology biotech: the equity case is driven by pipeline milestones, but the investment profile remains highly dependent on clinical readouts, partnering, and future financing needs. ([ir.pyxisoncology.com](https://ir.pyxisoncology.com/news-releases/news-release-details/pyxis-oncology-provides-business-update-and-reports-fourth?utm_source=openai))